Lirum Therapeutics (Lirum Therapeutics) Change In Payables And Accrued Expense : $1.57 Mil (TTM As of Dec. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Lirum Therapeutics Change In Payables And Accrued Expense?

Lirum Therapeutics's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was $0.00 Mil. It means Lirum Therapeutics's Accounts Payable & Accrued Expense stayed the same from Sep. 2023 to Dec. 2023 .

Lirum Therapeutics's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was $-0.04 Mil. It means Lirum Therapeutics's Accounts Payable & Accrued Expense declined by $0.04 Mil from Dec. 2022 to Dec. 2023 .

Lirum Therapeutics Change In Payables And Accrued Expense Historical Data

The historical data trend for Lirum Therapeutics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lirum Therapeutics Change In Payables And Accrued Expense Chart

Lirum Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

1.61

-0.04

Lirum Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Sep23	Dec23
Change In Payables And Accrued Expense	-	-	1.57	-	-

Lirum Therapeutics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.57 Mil.

Lirum Therapeutics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Lirum Therapeutics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Lirum Therapeutics (Lirum Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lirum Therapeutics Inc (NAS:LRTX) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

590 Madison Avenue, 21st Floor, New York, NY, USA, 10022

Website

https://www.lirumtx.com

Lirum Therapeutics Inc is clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases through the acquisition, development, and commercialization of novel drug candidates with compelling mechanisms of action, regulatory pathways, and commercial opportunities. Its product candidate, LX-101, formerly 765IGF-MTX, is a novel, clinical-stage, "next generation," precision-engineered targeted therapy directed to the IGF-1R.

Lirum Therapeutics (Lirum Therapeutics) Headlines

No Headlines